Skip to content
AnalystLens
Back to HALOCash Flow

Halozyme Therapeutics Free Cash Flow 2009-2026 | HALO

Annual FY2009–FY2025 · quarterly through Q3 FY2026

Latest annual · FY2025

$644.6M

+37.6%YoY vs FY2024Source: 10-KFY2025

From −$41.6M in FY2009 to $644.6M in FY2025.

By quarter▲▼ vs a year before
Fiscal yearQ1Q2Q3Q4
FY26$176M+15.0%$237M+141.2%$255M+45.4%Not reported
FY25$153M+21.8%$98M+84.4%$176M+54.2%$218M+24.0%
FY24$126M+66.5%$53M−18.4%$114M−12.1%$175M+75.8%
FY23$76M+59.8%$65M+66.1%$129M+88.7%$100M+24.5%
FY22$47M−18.5%$39M+8.0%$69M−43.4%$80M−2.7%
Share22%15%31%32%

Shaded by size: darkest is the largest quarter shown; ringed is the latest reported; a dash marks a quarter with no separate figure. Each quarter sits by its period-end date. Share: its typical part of the fiscal year.

Key Statistics

Trend DirectionGrowing
CAGR

+64.8%

FY2020
$53.0M
FY2025
$644.6M

5 years selected · on the chart

Free Cash Flow History

Year-over-year comparison from 10-K annual reports

  1. $644.6M
YoY changeLargest recent move+462.8%in FY21Latest +37.6%

3 older moves run past ±150% (largest +462.8%); point at, tap or drag across the bars to read one.

Free Cash Flow, period by period

PeriodValueChangeSource
FY2025$644.6M+37.6%10-K
FY2024$468.4M+25.5%10-K
FY2023$373.3M+58.6%10-K
FY2022$235.3M−21.0%10-K
FY2021$298.0M+462.8%10-K
FY2020$53.0M+159.2%10-K
FY2019−$89.5M−65.2%10-K
FY2018−$54.2M−140.8%10-K
FY2017$132.7M+348.0%10-K
FY2016−$53.5M−35.7%10-K
FY2015−$39.4M+19.3%10-K
FY2014−$48.9M+5.3%10-K
FY2013−$51.6M+21.4%10-K
FY2012−$65.7M−87.0%10-K
FY2011−$35.1M+23.7%10-K
FY2010−$46.0M−10.6%10-K
FY2009−$41.6M—10-K

What is Halozyme Therapeutics's current free cash flow?

Halozyme Therapeutics (HALO) annual free cash flow for 2025 was $644.6M, a 37.62% increase from 2024. Halozyme Therapeutics free cash flow for the quarter ending September 30, 2026 was $255.2M.

What was Halozyme Therapeutics's free cash flow in 2024?

Halozyme Therapeutics annual free cash flow for 2024 was $468.4M, a 25.47% increase from 2023.

What was Halozyme Therapeutics's free cash flow in 2023?

Halozyme Therapeutics annual free cash flow for 2023 was $373.3M, a 58.64% increase from 2022.

What is Halozyme Therapeutics's 5-year free cash flow CAGR?

Halozyme Therapeutics free cash flow grew at a compound annual growth rate (CAGR) of 64.85% from FY2020 to FY2025, going from $53.0M to $644.6M over 5 years.

Company
Halozyme Therapeutics
Ticker
HALO
Sector
Healthcare
Industry
Biological Products, (No Diagnostic Substances)